Program
difamilast
Also written as “OPA-15406”, “1% OPA-15406 Ointment” and “0.3% OPA-15406 Ointment”.
Its studies are mostly in Dermatitis, Atopic, led by 3 companies.
Drug pageDifamilast: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 132 open or running | phase 3since Apr 7, 2019 | Oct 3, 2012 | Dec 2026phase 3 · NCT07173478 |
| Aurobindo Pharmaits history only | 20 open or running | phase 3since Oct 5, 2022 | Oct 5, 2022 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 2since Oct 21, 2016 | Oct 21, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eurofarma Laboratorios only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 21, 2016First study: phase 2 study in Dermatitis, AtopicFirst studyNCT02945657 · 32 enrolled · United States, Honduras, Panama
- Dec 9, 2017Named difamilastINNProposed as its International Nonproprietary Name in WHO's List 118 · before, OPA-15406
TargetBeta
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| apremilastrule | Amgen | phase 4 | 48 |
| ensifentrinerule | Merck | phase 3 | 17 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
The one study Eurofarma Laboratorios leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02945657Dermatitis, Atopic · United States, Honduras, Panama | 2 | Completed | Jun 8, 2017 | 32 |
How it is read
Names in the registry
- “OPA-15406”, 7 entries
- “1% OPA-15406 Ointment”, 3 entries
- “0.3% OPA-15406 Ointment”, 2 entries
- “Difamilast”, 2 entries
- “1% OPA-15406”, 2 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 16 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.